The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Oral semaglutide for the treatment of type 2 diabetes
Abstract
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction. Currently, all approved members of the class require administration by injection. Areas covered: This manuscript reviews oral semaglutide—an experimental GLP-1 receptor agonist in phase-3 clinical development. Available pharmacological and clinical data of the drug are reviewed, and important end-points described. Expert opinion: Oral peptide delivery has become possible with the discovery of absorption enhancers. The clinical development program of once-daily oral semaglutide has shown superiority in reducing glycosylated hemoglobin and body weight in comparison with placebo and active comparators (sitagliptin, liraglutide, and empagliflozin). Safety and tolerability of oral semaglutide is in line with injectable members of the class. Delayed gastric emptying, local increase in pH, and enhanced absorption do not seem to affect the exposure of a number of other oral drugs that have been tested (metformin, digoxin, oral contraceptive ethinylestradiol/levonorgestrel, lisinopril, warfarin, furosemide and rosuvastatin). Clinical questions for further investigation include the effectiveness and safety of oral semaglutide in cardiovascular indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Challenges for the oral delivery of macromolecules
Goldberg, M., & Gomez-Orellana, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1067 · Cited by 544
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Bailey, R. A., Wang, Y., Zhu, V., & Rupnow, M. F. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-415 · Cited by 247
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0649-2 · Cited by 135
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Bækdal, T. A., Thomsen, M., Kupčová, V., Hansen, C. W., & Anderson, T. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1131 · Cited by 103
Bain, S. C., Mosenzon, O., Arechavaleta, R., Bogdański, P., Çömlekçi, A., Consoli, A., Deerochanawong, C., Dungan, K. M., Faingold, M. C., Farkouh, M. E., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13553 · Cited by 100
Exploring Differences in Drug Doses Between Japan and Western Countries
Arnold, F. L., Kusama, M., & Ono, S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.31 · Cited by 67
Bækdal, T. A., Breitschaft, A., Navarria, A., & Hansen, C. W. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1488965 · Cited by 59
Research works printed but not linked: 9
- Armstrong C., 2017, Am Fam Physician, 95, 40
- Buckley ST, 2017, Diabetes, 66, 1206
- Baekdal TA, Blicher TM, 2017, Diabetes, 66
- Granhall C, 2017, Diabetes, 66
- Connor A, Borregaard J, 2017, Diabetes, 66
- Baekdal TA, Borregaard J, 2017, Diabetes, 66
- Thomsen M, 2017, Diabetes, 66
- Jordy AB, 2018, Diabetes, 67
- Borregaard J, 2017, Diabetes, 66
Cited by
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“parable to the once-weekly subcutaneous preparation was approved [61,62].”
BackgroundStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundVerma, S., Goand, U. K., Husain, A., Katekar, R. A., Garg, R., & Gayen, J. R. (2021) · Drug Development Research · doi:10.1002/ddr.21832 · Cited by 151
“Early on, 300 mg was defined as the most suitable dose for the molecule and was used in clinical development of semaglutide (Hedrington & Davis, 2019).”
MethodRanjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 110
Advances and future perspectives in epithelial drug delivery
Mohammed, Y., Holmes, A. M., Kwok, P. C. L., Kumeria, T., Namjoshi, S., Imran, M., Matteucci, L., Ali, M., Tai, W., Benson, H. A., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114293 · Cited by 104
Metadata
- Authors
- Hedrington, M. S., & Davis, S. N.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Davis, Stephen N.
- ORCID
- Davis, Stephen N.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-11-30
- Volume
- 20
- Issue
- 2
- Pages
- 133-141
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2903342525
- Cited by
- 44
- References
- 17
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 9 · 2020: 10 · 2019: 9
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- not funded
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, GLP-1 receptor agonists, type 2 diabetes, absorption enhancers, HbA1c, weight loss, drug-drug interactions, drug safety and tolerability, cardiovascular effects, antihyperglycemic therapy
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides, Humans, Hypoglycemia, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral semaglutide for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1080/14656566.2018.1552258
- The paper
- Hedrington, M. S., & Davis, S. N. (2019). Oral semaglutide for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2018.1552258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.